Stefan Haneder MD, Presenter: Nothing to Disclose

Ulrike I. Attenberger MD, Abstract Co-Author: Nothing to Disclose

Stefan Oswald Schoenberg MD, PhD, Abstract Co-Author: Nothing to Disclose

Christian Loewe MD, Abstract Co-Author: Nothing to Disclose

Javier Arnaiz Garcia MD, Abstract Co-Author: Nothing to Disclose

Henrik J. Michaely MD, Abstract Co-Author: Consultant, Bayer AG

Intraindividual comparison of the diagnostic performance of Dotarem® (0.5M)-enhanced Magnetic Resonance Angiography (MRA) and Gadovist® (1.0M)-enhanced MRA at 3-Tesla.

Prospective, single-center, randomized, cross-over, comparative, double-blind study. 14 among 20 included patients (61.5±8.1 years) with peripheral arterial occlusive disease (stage II/III) were evaluated (6 received only one MRA). After injection of 0.1mmol/kg BW of either Dotarem® (flow rate 1.0ml/s) or Gadovist® (flow rate 0.5ml/s) MRA was acquired with continuous moving table technology (Magnetom TimTrio). Vascular territories explored were aorto-iliac, femoral, popliteal, calf, foot. The primary criterion was the overall image quality (5-point-scale) assessed in a blinded manner by two off-site and two on-site readers. Secondary criteria were the diagnostic confidence (5-point-scale), signal intensity (signal/contrast to noise ratios SNR/CNR), number of assessable arterial segments and detection of significant stenosis (>50%), collateral circulation visualization, pedal vessel and smaller branches visualization, venous overlap and safety.

The overall image quality (excellent/more than adequate) was better rated with Dotarem® than with Gadovist® (100% vs. 78.6%, 100% vs. 92.9%, 100% vs. 85.7%, 100% vs 85.7% for readers 1,2,3,4, respectively). Similar results were found for the excellent/high diagnostic confidence (100% vs. 92.9%, 100% vs. 92.8%, 100% vs. 85.8%, 92.9% vs. 85.7%). Significantly higher SNR/CNR values were obtained for Gadovist® compared to Dotarem® (26.1±10.5/23.4±9.9 vs. 22.7±10.3/20.2±9.7; p=0.01/0.01). For the secondary criteria, no differences between groups were reported. No adverse events were reported.  

Gadovist® yielded significantly higher SNR/CNR while Dotarem® was better rated in terms of overall image quality and diagnostic confidence though not statistically significant.

MRA of the lower extremities can be acquired with high quality with either gadobutrol or gadoterade with a dose of 0.1mmol/kg at 3.0T.

Haneder, S, Attenberger, U, Schoenberg, S, Loewe, C, Arnaiz Garcia, J, Michaely, H, Intraindividual Evaluation of Gadoterade-enhanced MRA Compared to Gadobutrol-enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Disease.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11005336.html